DNAJA3

Across TCGA pan-cancer cohorts, DNAJA3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DNAJA3 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DNAJA3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNAJA3 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where DNAJA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.402	0.811	.001	41	view →
GBM	OS	Tertile	All	0.933	0.773	.007	11	view →
PDAC	OS	Tertile	II,III,IV	0.798	0.938	.003	7	view →
LSCC	DFS	Median	II,III,IV	0.880	0.687	.027	6	view →
LUAD	DFS	Quartile	III,IV	0.875	0.372	.027	5	view →
HNSC	OS	Median	All	1.000	0.960	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DNAJA3–CCRCC (DFS)

Open the CCRCC breakdown →